Biogen (Nasdaq: BIIB) has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for a total potential consideration of up to USD 1 billion. The US-based acquirer said the deal adds multiple anti-inflammatory assets to its immunology pipeline, with the lead program having entered Phase I development in July 2026.
Under the deal terms, Biogen made an undisclosed upfront cash payment to RayThera's shareholders, who remain eligible for clinical and regulatory milestone payments that constitute the predominant share of the total potential consideration. No royalty terms were disclosed. Biogen assumes full global responsibility for development, manufacturing, and commercialization of the acquired assets. The deal was first announced in June 2026.
RayThera's portfolio comprises multiple small-molecule anti-inflammatory candidates designed to treat immune-mediated conditions across a range of indications. Specific targets and mechanisms of action were not disclosed by either company. The lead candidate is reportedly now in Phase I, though details have not been made public.